Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, APL, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, real-world evidence, Adverse Events, Monoclonal Antibody Therapy, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, APL, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, real-world evidence, Adverse Events, Monoclonal Antibody Therapy, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
Monday, December 12, 2022: 2:45 PM-4:15 PM
R02-R05
(Ernest N. Morial Convention Center)
Moderators:
Abhay Singh, MD, MPH, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic Foundation
and
Justin Watts, MD, Sylvester Comprehensive Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
These six abstracts report on advances in targeted therapy in AML, including targeted inhibition of FLT3, IDH2, and PML-RARA, sorafenib use in CBF-AML, and gemtuzumab in NPM1-mutant AML.
2:45 PM
3:00 PM
3:15 PM
3:30 PM
3:45 PM
4:00 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH